News Release

How interleukin-6 helps prevent allergic asthma and atopy by suppressing interleukin-2 signaling

Knowledge of this previously unrecognized mechanism may aid therapy for patients with interleukin-6 signaling mutations and hyper-IgE Syndrome, or HIES.

Peer-Reviewed Publication

University of Alabama at Birmingham

Beatriz Léon, Ph.D.

image: Beatriz Léon, Ph.D. view more 

Credit: UAB

BIRMINGHAM, Ala. – The immune system has a biological telecommunications system — small proteins known as interleukins that send signals among the leukocyte white blood cells to control their defense against infections or nascent cancer. Interleukin-6, or IL-6, is one of these key mediators of inflammation, and it can, as needed, provoke the immune system into attack against pathogens.

However, imbalances of IL-6 — too much or too little — can cause disease, even in the absence of infection. Excess IL-6 is central to the pathogenesis of inflammatory reactions like rheumatoid disease and cytokine storms, while mutations that interrupt IL-6 signaling are also harmful, causing allergic disorders known as atopy that affect the skin, airways or body, including atopic dermatitis, allergic airway inflammation and hyper-IgE Syndrome, or HIES.

Loss of IL-6 signaling was known to cause an increase in inflammatory T helper 2, or Th2, cells. T helper cells act like generals, ordering other immune cells into action. Now, an unrecognized mechanism of how interrupted IL-6 signaling creates Th2 bias, as well as the specific role of IL-6 signaling in that process, has been described by Beatriz Léon, Ph.D., and colleagues at the University of Alabama at Birmingham. Their study is published in the Nature journal Cellular & Molecular Immunology.

“Understanding how IL-6 contributes to suppress allergic sensitization may offer new strategies to prevent atopic disease in patients with deficient IL-6 signaling,” said Léon, an associate professor in the UAB Department of Microbiology.

The UAB team used a mouse model of allergic airway inflammation, induced by house dust mite allergen, to drive a response where naïve CD4+ T cells differentiate into Th2 cells. In the model, mice received intranasal allergen for three days, and then were again exposed to allergen two weeks later to induce an allergic reaction. In the experiments, researchers used T cells of various genetic backgrounds and also used various biological inhibitors, such as antibodies against interleukins or against interleukin receptors.

Researchers found that IL-6 signaling in allergen-specific T cells was needed to suppress commitment to the harmful Th2 lineage. This mechanism is distinct, but complementary to, a previously described suppression mechanism involving interleukin-12 and the Tbet transcription factor.

The UAB team found that the harmful Th2 cell lineage commitment in their model required strong and prolonged signaling by interleukin-2, or IL-2, in cells unable to make or respond to IL-6. In wild type T cells, IL-6 shuts down IL-2 signaling early in T-cell activation to inhibit Th2 cell priming.

Mechanistically, IL-6 acts to upregulate SOCS3, the Suppression of Cytokine Signaling 3 protein, which is a negative-feedback inhibitor of certain cytokines that bind to receptors on the surface of cells. In the absence of SOCS3, binding of those cytokines activates the JAK/STAT internal signaling pathway that leads to altered gene expression. Cytokines is a general term for signaling proteins that include not only interleukins, but also interferons and growth factors.

SOCS3 is known to inhibit internal signaling by inhibiting the kinase activity of the JAK1 protein. In further support of their mechanism, Léon and colleagues found that a selective inhibitor of JAK1 was able to prevent Th2 cell priming in cells that did not receive IL-6 signaling, showing that IL-6 suppression of the harmful Th2 bias acted through inhibition of the JAK/STAT pathway.

The UAB group also found that IL-6 had to act early — the first two days after T-cell priming with house dust mite allergen — to turn off IL-2 signaling.

“Taken together, our data demonstrate that IL-6 signaling in allergen-specific T cells is essential for preventing Th2 development by counteracting IL-2-driven pro-Th2 signals,” Léon said. “Our data provide insights into the immunological processes behind skewed Th2 responses in patients with defective IL-6 signaling or exposed to environmental factors that lead to decreased IL-6 synthesis.”

First author of the study, “IL-6 prevents Th2 cell polarization by promoting SOCS3-dependent suppression of IL-2 signaling,” is Holly Bachus, UAB Department of Medicine, Division of Clinical Immunology and Rheumatology.

Co-authors with Léon and Bachus are Erin McLaughlin, Crystal Lewis, Dave Durell Hill and Alexander F. Rosenberg, UAB Department of Microbiology; Amber M. Papillion and André Ballesteros-Tato, UAB Department of Medicine, Division of Clinical Immunology and Rheumatology; and Etty N. Benveniste, UAB Department of Cell, Developmental and Integrative Biology.

Support came from UAB and National Institutes of Health grants AI116584, AI150664 and AI162698.

At UAB, the departments of Microbiology, Medicine, and Cell, Developmental and Integrative Biology are part of the Marnix E. Heersink School of Medicine.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.